Management - Starpharma

Management

	Jackie Fairley, BSc, BVSc (Hons), MBA, GAICD, FTSE Chief Executive Officer Dr Jackie Fairley has more than 30 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding/Hospira (now part of Pfizer). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. She holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from the University of Melbourne and was a practicing veterinary surgeon prior to joining CSL. Whilst at CSL she obtained an MBA from the Melbourne Business School where she was the recipient of the prestigious Clemenger Medal. Jackie currently also sits on the board of the Melbourne Business School, listed investment company Mirrabooka.
	Tony Eglezos, BSc (Hons), PhD, MBA Vice President, Business Development Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia. Most recently he was Director Commercial Operations, Pharmaceuticals and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.
	David Owen, BSc (Hons), PhD Vice President, Research Dr Owen has extensive experience in medicinal chemistry and biochemistry, and in managing teams focused on commercially directed drug discovery. He has held several positions in the biotech industry including Mimotopes, Cerylid and Glykoz and gathered extensive international experience in biotechnology and pharmaceutical research and development. Since joining Starpharma David has driven the drug delivery programs by developing and executing a number of successful proof-of-concept studies. The results from these studies have led to a number of commercial partnerships such as Stiefel a GSK company, Lilly and AZ, as well as driving Starpharma's own internal drug delivery program focused on an improved dendrimer-docetaxel formulation.
	Jeremy Paull, BSc (Hons), PhD Vice President, Development and Regulatory Affairs Dr Paull leads Starpharma’s preclinical and clinical development programs, and the Company’s interactions with international regulatory authorities related to these programs. Jeremy previously led Starpharma’s NIH -funded programs, and is responsible for managing successful collaborations with the Company’s many international research and commercial development partners. The development and regulatory team led by Jeremy is responsible for the advancement of the VivaGel® standalone product through late-stage development and commercialisation, the development and commercialisation of the VivaGel® condom product, and the progression of Starpharma’s DEP™ technology, including DEP™ docetaxel, through preclinical and clinical development. Jeremy joined Starpharma in 2001 after working previously at medical technology company, Norwood Abbey, and completing a PhD in pharmacology at Monash University, Melbourne, Australia, prior to that.
	Nigel Baade, BCom , CPA, Grad Dip Arts (Development) Chief Financial Officer & Company Secretary Mr Baade is a CPA -qualified accountant with extensive experience in the pharmaceutical and biotechnology industries. Appointed as CFO on 1 January 2009, and Company Secretary in December 2013, he is responsible for the financial control and compliance of the Group. Mr Baade has experience in project and cost management of research activities, commercialisation of global business development opportunities, public and private equity raising and grant funding compliance. Prior to joining Starpharma as Financial Controller in 2006, he has held positions at Hagemeyer, Cerylid Biosciences, Faulding (Hospira) and UMT (Fonterra). He holds qualifications from University of Tasmania and Monash University.
	Filippa Shub, Registered Patent and Trademark Attorney, B.Sc (Biol), M.Sc (Prlm), GDip IP Law, MBA, FIPTA Director of Intellectual Property Ms Shub is a qualified Patent and Trade Mark Attorney with responsibility for managing the Intellectual Property assets of the Company. She has more than 20 years’ experience in Research, Commercialisation and Intellectual Property. Before joining Starpharma Ms Shub worked with both legal firms and biotechnology companies in Australia and USA, including Davies, Collison Cave, Allens Arthur Robinson, Norwood Abbey and CSL.